Literature DB >> 25146514

[The prevalence and clinical significance of arthritis in patients with systemic sclerosis].

Chanyuan Wu1, Qian Wang1, Dong Xu1, Mengtao Li1, Yong Hou1, Xiaofeng Zeng2.   

Abstract

OBJECTIVE: To explore the prevalence and independent influencing factors of arthritis in Chinese patients with systemic sclerosis (SSc).
METHODS: A total of 248 SSc patients were enrolled in this prospective cross-sectional study in Peking Union Medical College Hospital. Demographic, clinical and laboratory data were compared in arthritis group and non-arthritis group.
RESULTS: Of 248 Chinese SSc patients, mean age of onset was (37.1 ± 13.7) years old and disease duration was (7.4 ± 5.2) years. Overall prevalence of arthritis was 41.1% (102/248). The presence of arthralgia(95.1% vs 15.1%), muscle weakness (38.2% vs 24.7%), short of breath (60.8% vs 45.2%), and intestinal lung disease (64.7% vs 49.3%) occurred more frequently in patients with arthritis than those without arthritis (P < 0.05). The elevation of C reactive protein, anti-Sm and anti-cyclic citrullinated peptide were more common in arthritis group than in non-arthritis group (61.4% vs 43.9%, 11.4% vs 2.5% and 28.1% vs 2/16, respectively). There were no obvious differences in the Rodnan score, digital ulcers, pulmonary arterial hypertension, and six-minute walk test between two groups (P > 0.05).
CONCLUSION: This study reveals the significant prevalence of arthritis in a large cohort of SSc patients in China. Compared to non-arthritis patients, the SSc patients with arthritis have a more severe inflammation reaction and a higher rate of intestinal lung disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25146514

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  1 in total

1.  Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?

Authors:  Ramya Janardana; Aswin M Nair; Ajit K Surin; John Anthony Jude Prakash; Mahasampath Gowri; Debashish Danda
Journal:  Clin Rheumatol       Date:  2019-07-15       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.